Latest Research Highlights (UK + EU Studies 2022–2025)

Basic Sildalis Information

• INN (International Nonproprietary Name): Sildalis does not have an official INN; it is a combination of sildenafil citrate (INN: sildenafil) and tadalafil (INN: tadalafil).
• Brand Names Available In United Kingdom: Sildalis is marketed online as a non-innovator combination drug and is primarily available through international online pharmacies and unofficial distributors rather than registered UK pharmacies.
• ATC Code: Sildenafil — G04BE03; Tadalafil — G04BE08.
• Forms & Dosages: Tablet formulation; typical strength sold is 100 mg sildenafil + 20 mg tadalafil, in blisters of 6–20 tablets.
• Manufacturers In United Kingdom: Not specified.
• Registration Status In United Kingdom: Not registered with MHRA as a combined product.
• OTC / Rx Classification: Prescription-only where sildenafil or tadalafil are regulated; often sold online without prescription by unregulated suppliers.

Are there any robust trials showing Sildalis is safe and more effective than single agents?

Recent UK and EU surveillance (2022–2025) highlights two consistent findings: there are no regulatory clinical trials for combined sildenafil+tadalafil products such as Sildalis.

Small observational reports from EU sexual health clinics describe anecdotal improved spontaneity for some patients using combination pills, but these are not randomised controlled trials and have limited sample sizes.

Pharmacokinetic modelling papers from EU academic centres (2023–24) warn that combining a rapid‑onset PDE5 inhibitor like sildenafil with a long‑half‑life agent such as tadalafil increases cumulative exposure risk.

The main safety concerns noted are additive hypotension and higher rates of visual and musculoskeletal adverse events when exposures overlap.

MHRA Yellow Card trend analyses (2022–25) emphasise that unregistered online combination products are over‑represented in adverse reports compared with licensed monotherapy purchases.

Policy briefs from UK sexual health bodies therefore recommend against unsupervised use of such combinations pending formal clinical trials.

Preferable summary table of evidence type, sample sizes and key outcomes:

Clinical Effectiveness In The United Kingdom

What will the NHS base treatment decisions on: single agents or combinations?

There is no peer‑reviewed UK trial data for Sildalis specifically, and the NHS evaluates sildenafil and tadalafil individually when making treatment recommendations.

Sildenafil typically has a predictable onset of action around 30–60 minutes and is familiar to prescribers as Viagra or generic sildenafil tablets.

Tadalafil provides a longer therapeutic window—up to 36 hours in many patients—and is available as Cialis or tadalafil tablets with on‑demand and daily regimens.

The claimed benefit of Sildalis (rapid onset plus prolonged action) is pharmacologically plausible but remains unproven and carries an additive adverse‑event risk compared with monotherapy.

Patient‑reported outcome measures used by NHS services include the International Index of Erectile Function (IIEF) and treatment satisfaction scores; these tools favour familiar, approved regimens with known safety profiles.

Clinicians in urology and sexual health clinics report worse tolerability when exposures to multiple PDE5 agents overlap, particularly regarding headaches, flushing and dizziness.

Practical NHS advice is to start with a single approved agent—Viagra Connect where applicable for OTC sildenafil or prescription tadalafil—and only change strategy under clinical supervision.

Indications And Expanded Uses

What are the licensed uses of sildenafil and tadalafil in the UK?

Official MHRA and EMA indications apply to each component separately: sildenafil is licensed for erectile dysfunction and, at different doses and formulations (Revatio), for pulmonary arterial hypertension.

Tadalafil is licensed for erectile dysfunction and, in specified regimens, for benign prostatic hyperplasia (Cialis for BPH protocols).

Sildalis has no MHRA approval as a combined product and therefore carries no official combined indication.

Off‑label use of combinations is limited in NHS practice and is mostly patient‑driven via online purchases rather than clinician‑initiated prescribing.

In NHS care, expanded uses such as daily tadalafil for BPH or ED are performed using licensed tadalafil doses; simultaneous prescribing of full‑dose sildenafil and tadalafil is uncommon and generally discouraged due to additive vasodilatory effects.

• Licensed Uses: Sildenafil for ED; tadalafil for ED and BPH (per respective licences).
• Off‑Label/Combination Use: Not recommended without specialist review; largely unsanctioned market activity.

Conditions where combination use would be contraindicated or require caution include concurrent nitrate therapy, unstable cardiovascular disease and use of riociguat.

Composition And Brand Landscape

What is inside a Sildalis tablet and who supplies it?

Composition: per available product information, Sildalis tablets typically contain 100 mg sildenafil citrate plus 20 mg tadalafil in a single tablet.

Brand landscape: Sildalis is not produced by originator companies such as Pfizer or Eli Lilly.

Manufacture is largely by generic manufacturers often based in India or by web suppliers, with examples including firms like RSM Enterprises and Sunrise Remedies in export listings.

Packaging commonly presents red, oval tablets in blisters and may bear labels in English or Russian depending on the supplier.

In the UK, legitimate alternatives remain Viagra/Viagra Connect for sildenafil and Cialis for tadalafil, supplied via prescription or regulated OTC pathways for certain sildenafil strengths.

Contraindications And Special Precautions

Could taking Sildalis be dangerous with my other medicines or health problems?

Absolute contraindications for the combination follow the guidance for the individual components and include known hypersensitivity to sildenafil or tadalafil.

Concurrent use with nitrates, including short‑acting nitroglycerin and longer‑acting nitrate formulations, is strictly contraindicated because of the risk of life‑threatening hypotension.

Use of riociguat for pulmonary hypertension is also strictly contraindicated when taking PDE5 inhibitors.

Relative contraindications include significant hepatic or renal impairment, recent stroke or myocardial infarction, unstable angina and severe heart failure.

Rare retinal disorders such as retinitis pigmentosa warrant specialist review before prescribing PDE5 inhibitors.

Elderly patients should start at lower doses and have cardiac assessment where indicated.

Practical pharmacist checklist before supply:

• Confirm no nitrates or riociguat in the current medication list.
• Review cardiovascular history and recent cardiac events.
• Check liver and kidney impairment and adjust doses accordingly.
• Advise on driving and alcohol—visual disturbance and dizziness may affect ability to drive per DVLA guidance.

Dosage Guidelines

How should dosing be approached if a patient asks about Sildalis?

There are no MHRA or NHS‑endorsed dosing guidelines for Sildalis as a combined product.

Individual component guidance still applies: sildenafil on‑demand dosing is usually 25–100 mg taken 30–60 minutes before sexual activity.

Tadalafil options include on‑demand 10–20 mg or daily low‑dose regimens of 2.5–5 mg depending on the licensed indication.

The common commercial Sildalis tablet strength is 100 mg sildenafil + 20 mg tadalafil and is typically advised by sellers as one tablet 30–60 minutes before activity, not more than once in 24 hours.

UK clinicians consider this combined full dosing a high exposure and would not recommend routine simultaneous full doses without cardiology review and detailed medication reconciliation.

Dose adjustment rules stem from the monographs: use lower starting doses in elderly patients and in those with significant renal or hepatic impairment.

Definition list contrasting regimens:

• On‑demand: Medication taken prior to sexual activity; sildenafil common choice for predictable onset.
• Daily: Low‑dose tadalafil provides continuous coverage and is used when frequent sexual activity or BPH symptom relief is desired.

Interactions Overview

What medicines or substances increase risk when combined with Sildalis?

The most important interactions are shared by both sildenafil and tadalafil and therefore apply to any combined product.

Concurrent nitrates and riociguat are absolute contraindications because of severe hypotension risk.

CYP3A4 inhibitors, such as some macrolide antibiotics, certain HIV protease inhibitors and azole antifungals, can increase sildenafil and tadalafil levels and raise the likelihood of adverse effects.

Strong CYP3A4 inducers like rifampicin may reduce PDE5 efficacy.

Alcohol potentiates vasodilatory and orthostatic effects and increases the chance of dizziness and syncope.

Grapefruit juice can alter CYP3A4 exposure and should be avoided with high PDE5 doses.

Pharmacovigilance data suggest interaction‑related events are more commonly reported from non‑regulated online purchases than from regulated supply chains.

Cultural Perceptions And Patient Habits

Why do many UK patients still buy medicines online despite NHS services?

UK patients often combine discretion with a high level of trust in NHS clinicians and community pharmacists for sexual health issues.

Online forums and discussion boards show a demand for perceived "stronger" or longer‑acting options, which fuels interest in combination pills like Sildalis.

Stigma and reluctance to discuss erectile dysfunction face‑to‑face drive some people to use unregulated online suppliers rather than consult NHS services or high‑street pharmacists.

Regional differences exist: Scotland and Wales have growing primary‑care pharmacist services and local formulary guidance which can influence prescribing choices away from unsanctioned combinations.

High‑street chains such as Boots, LloydsPharmacy and Superdrug increasingly provide private sexual health consultations and e‑prescriptions which reduce unsafe self‑supply by offering regulated alternatives and pharmacist counselling.

Availability And Pricing Patterns

Can Sildalis be bought in the UK and how does cost compare with licensed treatments?

Sildalis is primarily sold online via international pharmacies and is not stocked by mainstream UK chains as a combination product.

Licensed alternatives such as Viagra, generic sildenafil and Cialis are available via NHS prescription or private purchase with price variation by pack size and service fees.

NHS prescription charges differ across the UK—England has a standard prescription charge, while Scotland, Wales and Northern Ireland have different exemption and charging arrangements.

High‑street private services charge consultation fees in addition to medicine costs, but these channels provide regulated medicines with pharmacist oversight.

Online unregulated suppliers may appear cheaper on a per‑tablet basis, but they carry the risk of counterfeit products, inaccurate labelling and lack of clinical screening.

For transparency, our online pharmacy lists Sildalis as available without a prescription with discreet delivery to United Kingdom in 5–14 days, but customers are advised of registration and safety concerns before purchase.

Comparable Medicines And Prescribing Preferences

Which licensed options should clinicians and patients consider before an unregulated combination?

NHS prescribing favours licensed monotherapy: sildenafil (Viagra or Viagra Connect) for on‑demand use and tadalafil (Cialis) for on‑demand or daily therapy depending on patient need.

Vardenafil (Levitra) is an alternative PDE5 inhibitor for those who do not tolerate sildenafil or tadalafil.

Clinicians decide based on individual efficacy, side‑effect profiles, comorbidities and potential drug interactions documented in the patient record.

Theoretical advantages of a combined product such as Sildalis—simultaneous rapid onset and long duration—must be balanced against lack of regulatory approval and increased adverse‑event probability.

• Pros of Licensed Monotherapy: Known safety profile, adjustable dosing, established guidance for interactions and contraindications.
• Cons of Unregulated Combination: Unproven benefit, unknown manufacturing quality, and higher potential for additive adverse events.

Frequently Asked Questions

Q1: Is Sildalis MHRA‑approved?

A1: No.

There is no MHRA registration for Sildalis as a combined sildenafil+tadalafil product according to available records.

Q2: Can I buy Sildalis without a prescription in the UK?

A2: Many online sellers market Sildalis without a prescription, but in regulated UK channels sildenafil and tadalafil are prescription‑only or supplied via controlled OTC pathways for specific strengths; unsupervised purchase increases safety risks.

Q3: What are the main risks of taking a combined product?

A3: Main risks include additive hypotension (especially with nitrates), priapism, vision changes and uncertain manufacturing quality.

Q4: What should I do if I have questions or concerns?

A4: Seek assessment from an NHS clinician or a registered private prescriber, and consult a community pharmacist for medication review; report suspected adverse reactions to the MHRA Yellow Card scheme.

Guidelines For Proper Use (Pharmacist Counselling And NHS Support)

How should pharmacists and prescribers handle queries about Sildalis or suspected use?

Start every consultation with a structured medical history that focuses on cardiovascular risk, current medicines (especially nitrates and riociguat) and any hepatic or renal impairment.

Use electronic tools such as Summary Care Records and electronic prescriptions to reconcile medicines and flag high‑risk interactions before supply.

Key counselling points include starting with a licensed monotherapy, limiting alcohol on dosing days, and seeking urgent help for erections lasting more than four hours.

Advise patients to stop any unsupervised combination product if they are taking nitrates and to seek immediate medical review.

Pharmacists should report adverse events from unregistered products to the MHRA Yellow Card scheme and document counselling in the patient record.

• Pharmacist Counselling Checklist: Cardiovascular history, medication reconciliation, DVLA/driving advice, and clear instructions on when to seek emergency care for priapism.
• Monitoring Steps: Annual review of comorbidities and recording patient‑reported outcomes using tools like IIEF where services provide follow‑up.

Delivery Across United Kingdom